Research On Restructuring Strategies Of "CHIATAI-BRIGHTGENE" Strategic Alliance From The New Medical Reform Situation

Under the role of China’s medical security mechanism,the medical insurance policy directly affects the development of generic drug raw material and preparation enterprises.With the implementation of consistency evaluation and centralized procurement,the competitive landscape of the generic pharmaceutical industry is facing a major change,and the focus of development strategies of related companies has shifted to improving cost control and innovation capabilities.There are many ways for pharmaceutical companies to cooperate in the industrial chain.As a loose organizational structure,the strategic alliance depends on a series of factors such as the strategic development direction,resource capabilities,and management level of the two parties.The formation of an alliance requires a combination of internal and external factors.Chiatai and Bright Gene have successfully established the integration of the entecavir API industry chain through the establishment of a strategic alliance,which is also affected by the medical reform measures.This article analyzes the internal and external environment of the alliance based on the theory of strategic alliances,combines resource-based theory and knowledge transfer theory,and then puts forward relevant restructuring strategies and suggestions based on actual conditions.The research of this article is divided into six chapters: Chapter One puts forward the research ideas and framework of this article in conjunction with the research background;Chapter II starts from the study of strategic alliances,and summarizes relevant domestic and foreign related research advances in combination with resource-based theory and knowledge transfer theory;Chapter III specifically analyzes the development status,compositional motivations,stability factors and exciting problem of the “ChiataiBright Gene” strategic alliance;Chapter 4 explore opportunities for alliance restructuring through internal and external environmental analysis and SWOT analysis;Chapter 5 proposes based on the theory and actual situation Alliance restructuring strategy and recommended measures;Chapter 6 summarizes the full text.In the theoretical research,the author first summarizes the different constitutive mechanisms of strategic alliances,and summarizes the relevant literature on alliance conflict optimization in combination with alliance stability factors.Specifically,the constituent factors of a strategic alliance mainly consider the motivations and expected goals of the participants in the alliance,while the stability and conflicts of the alliance are determined by multiple factors such as internal and external conditions,benefit distribution,and operating mechanisms.The restructuring and optimization of the alliance should be focused on.The re-investment of resources and the establishment of new alliance elements need to be considered in multiple dimensions in the case of different alliances.Part of the case study focuses on the study of the “Chiatai-Bright Gene” strategic alliance,and combines theory with practice to analyze and study the motivation,operational measures,and stability factors of the strategic alliance.By analyzing the external factors of the alliance,it is concluded that the change in the market competition pattern originates from the policy to guide the pharmaceutical industry to carry out supplyside reforms,and to solve the general situation of low quality,high prices and few innovations.Through analysis of the internal factors of the alliance,it is concluded that there is a certain degree of complementarity between the core resource capabilities of the two sides.The two parties have common goals for the future development of the enterprise and are willing to invest new resources in the alliance.Restructuring the alliance is not only in line with national policy guidance,but also Meet the needs of the enterprise development of both sides of the alliance.Through the analysis of the necessity and strategy of the alliance restructuring,the restructuring execution plan is determined,and a set of practical and feasible strategic opinions are summarized and corresponding measures are proposed.Based on the conclusions of the study,this paper proposes that the key to the restability of the strategic alliance of pharmaceutical companies lies in the reinvestment of resources to improve the alliance’s capabilities,the transfer of knowledge to form a technological innovation soil,the overall depth and breadth of the alliance,and the formation of a new round of stability in the alliance.At the same time,this article provides reference for the strategic alliance cooperation of other pharmaceutical companies with the same background.